Growth Hormone Axis Peptides: A Modern Review

Pulsatile growth hormone secretion from anterior pituitary somatotrophs is regulated by two opposing hypothalamic inputs — growth hormone-releasing hormone (GHRH) acting on the GHRH receptor, and somatostatin acting inhibitory at the somatostatin receptor — together with a third input from ghrelin acting at the growth hormone secretagogue receptor (GHS-R1a). The peripheral consequence of GH secretion is hepatic IGF-1 production, which mediates most of the systemic anabolic effects associated with the axis.

Pharmacological peptides that engage this axis fall into three families: GHRH analogs, growth hormone-releasing peptides (GHRPs / ghrelin mimetics), and IGF-1 analogs acting downstream of the axis. Each has distinct receptor targets and pharmacological characteristics.

Tesamorelin is a synthetic GHRH analog with an N-terminal trans-3-hexenoic acid modification that protects against DPP-4 cleavage and extends biological activity. It holds FDA approval for HIV-associated lipodystrophy, with a clinical-trial record that demonstrates reduction in visceral adipose tissue and improvements in lipid profile over 26–52 weeks.

CJC-1295 is a GHRH(1-29) analog with four amino-acid substitutions that confer enzymatic stability. The peptide exists in two forms — with and without the Drug Affinity Complex (DAC) lysine conjugate, which mediates covalent binding to serum albumin. CJC-1295 with DAC has a half-life measured in days, supporting weekly dosing; CJC-1295 without DAC has a half-life measured in minutes and is most often used in combination with a GHRP for acute pulsatile release.

The key mechanistic feature shared by both compounds is that they act upstream of the pituitary, so GH release remains under normal hypothalamic feedback control. This is a pharmacological distinction from exogenous recombinant GH administration, where the feedback loop is bypassed.

Growth hormone-releasing peptides are synthetic ghrelin mimetics that bind the GHS-R1a receptor on pituitary somatotrophs and hypothalamic neurons. The receptor activation triggers a pulsatile release of GH that is mechanistically distinct from the GHRH pathway, and the two work synergistically when co-administered.

The three principal compounds in the family — GHRP-6, GHRP-2, and ipamorelin — differ primarily in selectivity. GHRP-6 produces a substantial GH response but also elevates cortisol, prolactin, and ACTH and stimulates hunger via ghrelin pathway activation. GHRP-2 produces the largest GH response of the three but also elevates cortisol and prolactin. Ipamorelin is the selective compound: GH release without meaningful cortisol, prolactin, or aldosterone elevation at standard research doses.

For research protocols studying GH axis pharmacology specifically, ipamorelin is the preferred choice because the GH response is uncontaminated by cortisol or prolactin effects. For protocols where appetite stimulation or broader pituitary effects are part of the experimental question, GHRP-6 or GHRP-2 may be more appropriate.

The most commonly discussed combination in modern GH-axis research pairs a GHRH analog (CJC-1295) with a selective GHRP (ipamorelin). The mechanism is additive: GHRH increases the pool of releasable GH in the somatotroph, and the GHRP triggers the pulse. The combined response is larger than either compound alone.

The clinical-research rationale for using ipamorelin specifically in the combination is the cortisol/prolactin selectivity. A combination with GHRP-6 or GHRP-2 would produce the same additive GH effect but with broader pituitary activation.

IGF-1 LR3 (Long Arg3 IGF-1) is a recombinant analog of human IGF-1 with a 13-amino-acid N-terminal extension and an arginine substitution at position 3. These modifications reduce binding to IGF-binding proteins (IGFBPs), substantially increasing the free fraction of IGF-1 available to bind the IGF-1 receptor.

Unlike the GHRH and GHRP families, IGF-1 LR3 acts downstream of the pituitary and bypasses hypothalamic feedback regulation entirely. The pharmacology is therefore quite different: sustained elevation of IGF-1 receptor signaling rather than pulsatile GH release with downstream hepatic IGF-1 production.

The compound is primarily a research tool in cell-biology and tissue-culture contexts where direct IGF-1R engagement is desired. Translation to systemic clinical use is constrained by the bypass of normal feedback regulation.

For a clinician reading the literature, the most useful framing is: GHRH analogs increase the pool of releasable GH but preserve pulsatile pattern and hypothalamic feedback; GHRPs trigger acute pulses via a distinct receptor with selectivity differences between compounds; the combination of the two is additive at the somatotroph; and IGF-1 LR3 bypasses the axis entirely and acts at the downstream receptor.

Each has a distinct research application and the choice should be driven by which level of the axis the experimental question targets.

AOD-9604 is a C-terminal fragment of hGH (residues 177–191) with a tyrosine addition. It does not engage the GH receptor as a full agonist and is studied principally in lipolytic and metabolic contexts — the mechanism is distinct from the secretagogues reviewed above.

Follistatin-344 and PEG-MGF (mechano growth factor) sit at the intersection of the GH axis with skeletal muscle biology — follistatin via myostatin/activin antagonism, MGF as an IGF-1 splice variant — and are most relevant in musculoskeletal research rather than endocrinology proper.

The GH axis literature is one of the more pharmacologically well-characterized in modern peptide research, with multiple FDA-approved compounds (recombinant GH, tesamorelin) anchoring the clinical record. The secretagogue families discussed here are predominantly research tools and clinical investigational compounds, and the strength of the evidence varies considerably between compounds. A clinician evaluating any specific compound should look for the receptor-level pharmacology, the selectivity profile, and the available human PK/PD data — these three together provide a much clearer picture than indication-level summaries alone.